Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.

Tong XM, Feng L, Suthe SR, Weng TH, Hu CY, Liu YZ, Wu ZG, Wang MH, Yao HP.

J Immunother Cancer. 2019 Sep 13;7(1):250. doi: 10.1186/s40425-019-0732-8.

2.

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.

Yao HP, Feng L, Suthe SR, Chen LH, Weng TH, Hu CY, Jun ES, Wu ZG, Wang WL, Kim SC, Tong XM, Wang MH.

J Immunother Cancer. 2019 Apr 2;7(1):94. doi: 10.1186/s40425-019-0571-7.

3.

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.

Yao HP, Feng L, Suthe SR, Chen LH, Weng TH, Hu CY, Jun ES, Wu ZG, Wang WL, Kim SC, Tong XM, Wang MH.

J Immunother Cancer. 2019 Mar 14;7(1):75. doi: 10.1186/s40425-019-0525-0. Erratum in: J Immunother Cancer. 2019 Apr 2;7(1):94.

4.

RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.

Suthe SR, Yao HP, Weng TH, Hu CY, Feng L, Wu ZG, Wang MH.

Mol Cancer Ther. 2018 Dec;17(12):2654-2664. doi: 10.1158/1535-7163.MCT-18-0252. Epub 2018 Oct 1.

5.

Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.

Yao HP, Feng L, Weng TH, Hu CY, Suthe SR, Mostofa AGM, Chen LH, Wu ZG, Wang WL, Wang MH.

Mol Pharm. 2018 Aug 6;15(8):3260-3271. doi: 10.1021/acs.molpharmaceut.8b00298. Epub 2018 Jun 26.

PMID:
29944378

Supplemental Content

Loading ...
Support Center